Opendata, web and dolomites

HTS MALDI-TOF MDD SIGNED

MALDI-TOF mass spectrometry metabolite screening assays for drug discovery in human disease

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 HTS MALDI-TOF MDD project word cloud

Explore the words cloud of the HTS MALDI-TOF MDD project. It provides you a very rough idea of what is the project "HTS MALDI-TOF MDD" about.

sections    compare    assisted    final    lung    hts    centric    surface    boehringer    precision    fibrosis    significantly    screening    fluorescence    reported    chemical    label    industry    maldi    mass    corner    biology    assayed    mapping    reagent    metabolites    diverse    explored    simultaneously    limited    peptide    pharmaceutical    reproducibility    excellent    germany    validated    metabolomics    disease    pulmonary    fellowship    offers    samples    laser    throughput    cellular    drugs    detection    free    50    possibility    first    model    stone    cell    biomarkers    discovery    platform    molecules    readouts    provides    profile    unbiasly    date    comprehensibly    desorption    ingelheim    track    noise    tool    mostly    ionisation    imaging    protocol    vitro    fibrotic    time    metabolic    identification    flight    drug    matrix    tissue    assay    assays    manner    see    effect    tof    protein    validation    spectrometry    ms    screen    substances    quantification    small    ht    signal    unbiased   

Project "HTS MALDI-TOF MDD" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITY OF NEWCASTLE UPON TYNE 

Organization address
address: KINGS GATE
city: NEWCASTLE UPON TYNE
postcode: NE1 7RU
website: http://www.ncl.ac.uk/

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 212˙933 €
 EC max contribution 212˙933 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2019
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2020
 Duration (year-month-day) from 2020-04-01   to  2022-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITY OF NEWCASTLE UPON TYNE UK (NEWCASTLE UPON TYNE) coordinator 212˙933.00

Map

 Project objective

Discovery for drug targets is a key step within the process of drug development, and is the corner stone in the pharmaceutical industry. This is mostly achieved by high-throughput screening (HTS) approaches in which a large number of chemical substances are assayed for a specific effect or activity in diverse areas of biology. Mass spectrometry (MS) has become a widely adopted tool in this field as it offers the possibility to simultaneously track molecules in a label-free manner, provides excellent signal to noise, reproducibility, assay precision, and a significantly reduced reagent cost when compared to fluorescence-based assays. Matrix-assisted laser/desorption ionisation time of flight (MALDI-TOF) is the most validated surface ionisation method for HTS approaches, but reported applications of this technology have been limited to in vitro assays with simple readouts and to peptide/protein-centric activity assays. To date, comprehensive and unbiased metabolomics based HTS approaches for cellular assays with MALDI-TOF have not been explored. The objective of this fellowship is to set up a MALDI-TOF based cellular assay for HTS metabolomics drug discovery in order to identify a set of metabolites to screen which will enable us to unbiasly and comprehensibly measure, in a HT manner, how drugs affect different metabolic pathways while simultaneously mapping the metabolic profile of the cell. First, I will develop a robust protocol for the detection, identification, and quantification of ~50 small metabolites for cellular assays. Then, I will apply this protocol to track metabolites in a pulmonary fibrosis cellular model, as well as in fibrotic lung tissue sections using MS imaging. The goal is to compare a disease model with the control to see how drugs are affecting these metabolites, and to see if identified biomarkers can be used to identify disease in tissue samples. As a final validation step, I will implement this platform in Boehringer Ingelheim in Germany.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HTS MALDI-TOF MDD" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HTS MALDI-TOF MDD" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

MINT (2019)

Multifunctional Immunocompatible NanoTheranostics to modulate tumor microenvironment and improve treatment monitoring: A double blow to pancreatic cancer

Read More  

REFINTEG (2019)

The Canadian model of the public-private sponsorship for the integration of refugees: the case of Syrians and possible application in EU countries

Read More  

EyeGestLearn (2019)

Applying eye-tracking to investigate information uptake from co-speech gestures in online learning environments

Read More